Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis

International Journal of Clinical Pharmacology and Therapeutics

Volumn 47, Issue 1, 2009, Pages 61-64

  Hilger, Ralf A ^a   Richly, Heike ^a   Grubert, M ^a   Kredtke, S ^a   Thyssen, D ^a   Eberhardt, W ^a   Hense, J ^a   Schuler, M ^a   Scheulen, M E ^a  

^a UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

Author keywords

Hemodialysis; Pharmacokinetics; Renal impairment; Sorafenib

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SORAFENIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE 1 OXIDE; PYRIDINE DERIVATIVE; PYRIDINE N-OXIDE;

BLOOD SAMPLING; CASE REPORT; CONFERENCE PAPER; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG URINE LEVEL; ENZYME PHOSPHORYLATION; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; KIDNEY DYSFUNCTION; LIVER CELL CARCINOMA; MORNING DOSAGE; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SINGLE DRUG DOSE; ARTICLE; BLOOD; CHEMISTRY; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; KIDNEY DISEASE; METABOLISM; PATHOPHYSIOLOGY; RENAL REPLACEMENT THERAPY; TIME;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; BLOOD SPECIMEN COLLECTION; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; KIDNEY DISEASES; PROTEIN KINASE INHIBITORS; PYRIDINES; RENAL DIALYSIS; TIME FACTORS;

EID: 65349119300     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP47061     Document Type: Conference Paper

References (10)

1. Hilger RA, Scheulen ME, Strumberg D. The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie. 2002; 25: 511-518.
2. Hilger RA, Kredtke S, Hedley D, Moeller JG, Bauer RJ, Stellberg W, Seeber S, Scheulen ME, Strumberg D. ERK1/2 phosphorylation: a biomarker analysis within a phase I study with the new Raf kinase inhibitor BAY43-9006. Int J Clin Pharmacol Ther. 2002; 40: 567-568.
3. Hilger RA, Díaz-Carballo D, Bauer S, Kredtke S, Scheulen ME, Seeber S, Strumberg D. Circadian rhythm in the regulation of the MAP kinase pathway - pitfall in the determination of surrogate parameters? Int J Clin Pharmacol Ther. 2003; 41: 614-615.
4. Hilger RA, Kredtke S, Scheulen ME, Seeber S, Strumberg D. Correlation of ERK-phosphorylation and toxicities in patients treated with the Raf kinase inhibitor BAY 43-9006. Int J Clin Pharmacol Ther. 2004; 42: 648-649.
5. Kupsch P, Henning BF, Passarge K, Richly H, Wiesemann K, Hilger RA, Scheulen ME, Christensen O, Brendel E, Schwartz B, Hofstra E, Voigtmann R, Seeber S, Strumberg D. Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. Clin Colorectal Cancer. 2005; 5: 188-196.
6. Lathia C, Lettieri J, Cihon F, Gallentine M, Radtke M, Sundaresan P. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol. 2006; 57: 685-692.
7. Mross K, Steinbild S, Baas F, Reil M, Buss P, Mersmann S, Voliotis D, Schwartz B, Brendel E. Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors. Int J Clin Pharmacol Ther. 2003; 41: 618-619.
8. Pleiss U, Gerisch M, Seidel D. Syntheses of [2H3,15N], [14C]NexavarTM and its labelled metabolites. J Label Comp Radiopharm. 2006; 49: 603-613.
9. Richly H, Henning BF, Kupsch P, Passarge K, Grubert M, Hilger RA, Christensen O, Brendel E, Schwartz B, Ludwig M, Flashar C, Voigtmann R, Scheulen ME, Seeber S, Strumberg D. Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol. 2006; 17: 866-873.
10. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol. 2005; 23: 965-972.